Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 147

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 147
---
 development, primarily due to the increased size and duration of later-stage clinical trials. The actual probability of success for our product candidates may be affected by a variety of factors, including the safety and efficacy of our product candidates, conduct of clinical trials, investment in our clinical programs, competition, manufacturing capability, and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties 97

discussed above, we are unable to determine the duration and completion of costs of our research and development projects or if, when, and to what extent we will generate revenue from the commercialization and sale of LB-102or any future product candidates, if approved by the FDA and other applicable regulatory authorities. Our future research and development costs may vary significantly based on factors such as:

| • |     | the timing and progress of our clinical development activities; |

| • |     | the number and scope of preclinical and clinical programs we decide to pursue; |

| • |     | the amount and timing of any milestone payment due under an existing, or any future, license or collaboration 
 agreement or asset acquisition;                                                                               |

| • |     | the number of patients that participate in our clinical trials, and per participant clinical trial costs; |

| • |     | the number and duration of clinical trials required for approval of our product candidates; |

| • |     | the number of sites included in our clinical trials, and the locations of those sites; |

| • |     | delays or difficulties in adding trial sites and enrolling participants in our clinical trials; |

| • |     | patient drop-out or discontinuation rates; |

| • |     | potential additional safety monitoring requested by regulatory authorities; |

| • |     | the phase of development of our product candidates; |

| • |     | the efficacy and safety profile of our product candidates; |

| • |     | the timing, receipt, and terms of any approvals from applicable regulatory authorities, including the FDA and non-U.S. regulators; |

| • |     | maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our 
 product candidates;                                                                                            |

| • |     | hiring and retaining additional personnel such as clinical, quality control, scientific, commercial, and 
 administrative;                                                                                          |

| • |     | maintain, expand, and protect our intellectual property portfolio; |

| • |     | establish sales, marketing, distribution, manufacturing, supply chain, and other commercial infrastructure in the